MedTrace Logo

A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer

NCT05385809 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-11-09

No results posted yet for this study

Summary

This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally advanced or stage IV gastric cancer/gastroesophageal junction carcinoma.

Conditions

  • Unresectable Gastric Cancer

Sponsors & Collaborators

Principal Investigators

  • Xiangdong Cheng, MD, PhD · Zhejiang Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-07-30
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385809 on ClinicalTrials.gov